According to a new market report introduced by ResearchKart.com, In the next five years, the global asthma market andCOPDdrug market is expected to grow slowly, primarily because of expiry of patents of leading drug brands and price erosion inthe market.
However, by 2017, few novel drugsare expectedto enter the asthma andCOPD market, which will drive future growth.
For more details Read at:http://www.researchkart.com/product/11374/Asthma-and-COPD-Drug-Market-Global-Industry-Analysis-Market-Size-Share-Trends-Growth-and-Forecasts-2010-2017.html
In the overall Asthma and COPD market, Advair remained the market leader with USD 7,802 million in 2011 and is expected to reach USD xxxx million in 2014. Singulair is the second largest drug in terms of revenue at UD 5479 million in 2011. The patent that provides U.S. market exclusivity for Singulair will expire in August 2012.
It is expected that within 2-3 years following patent expiration, it will lose substantially all U.S. sales of Singulair,
with most of those declines coming in the first full year following patent expiration. Also, the patent that provides market exclusivity for Singulair will expire in a number of major European markets in February 2013 and sales of Singulair in those markets will decline significantly thereafter. The patent that provides market exclusivity for Singulair in Japan will expire in 2016.
Asia Pacific region commanded for the largest share of global Asthma patients in 2010. The North America region will have the fastest growth rate for asthma patients at a CAGR of 3.9% in the world during 2010 - 2017.
Globally, patients numbers are increasing continuously primarily due to cigarette smoking, continual exposure to hazardous particles or gases, increase in urbanization, change in lifestyle, and genetic factors. The growing number of asthmatics people from china and other economies will drive the revenue growth for the Asthma and COPD drugs market.
RESEARCH KART CORP